Tonghua Dongbao Pharmaceutical Co (600867) Fair Value & Analysis

Healthcare · CN · Market cap 14.8B CNY

Analysis

Tonghua Dongbao Pharmaceutical Co (600867) currently trades at ¥7.42, while our model-based Fair Value estimate is ¥6.19 — implying the stock looks roughly 16.6% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Tonghua Dongbao Pharmaceutical Co., Ltd. researches, develops, produces, and markets pharmaceuticals in China. It offers human insulin injections; insulin glargine injections; insulin aspart injections; liraglutide injections; and proprietary Chinese medicine. The company also provides insulin pen and pen needles; and chronic disease management platform, a diabetes management platform for drug treatment, blood glucose monitoring, and patient education. In addition, it offers chemical drugs, such as repaglinide, sitagliptin phosphate, and metformin hydrochloride tablets. Tonghua Dongbao Pharmaceutical Co., Ltd. was founded in 1985 and is headquartered in Tonghua, China.

Open the full interactive analysis →

Similar stocks

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.